NCT05622032|Completed
Loading search results
Sponsor study identifier
observational
52
1 country
1
Study Start
September 20, 2022
Actual (reported)Primary Completion
March 25, 2025
Actual (reported)Study Completion
March 25, 2025
Actual (reported)The goal of this observational study is to assess the risk of viral infections in patients receiving hematopoietic stem cell transplantation (HSCT) from a haploidentical donor compared to those who receive HSCT from a HLA-matched donor. The main question it aims to answer is: to describe which viruses are replicating in the blood of the above two patient groups on the day of transplantation and at 1, 3 and 6 months after transplantation. Blood samples taken as part of routine care on the day of transplantation and at 1, 3 and 6 months post-transplantation visits are analyzed and the types and amount of viruses detected in the two groups of patients are described.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 25, 2025
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 20, 2022
Actual (reported)November 10, 2022
Actual (reported)November 18, 2022
Actual (reported)March 25, 2025
Actual (reported)March 25, 2025
Actual (reported)Describe the blood virome in haploidentical and HLA-matched allo-HSCT recipients during the first 6 months after transplantation.
Describe the types of viruses detected as well as their frequency in the blood virome of haplo- HSCT patients compared to the HLA-matched group by metagenomic next generation sequencing
6 months after transplantation
Patients receiving HSCT from a haploidentical donor. They also receive a treatment called cyclophosphamide as part of the protocol to prevent graft versus host disease at day 3 and 4 after transplantation.
Patients who receive HSCT from a HLA-matched donor.
Adult patients receiving allogeneic HSCT at the Geneva University Hospitals from a haploidentical or from an HLA-matched donor, who signed the informed consent form before transplantation for inclusion in the prospective cohort of "Infectious disease in hematopoietic stem cell transplant patients".
Contact the study team to confirm eligibility.
Geneva University Hospitals
Geneva, 1205, Switzerland
Blood specimens originating from the above biobank, collected at 4 time points (day 0, 30, 90 and 180) after transplantation.
Laurent Kaiser, Pr, MD
University Hospital, Geneva
52 participants (actual enrollment reported by the registry).
First Submitted
November 10, 2022
First Posted
November 18, 2022
Study Start
September 20, 2022
Actual (reported)Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
Primary Completion
March 25, 2025
Actual (reported)Study Completion
March 25, 2025
Actual (reported)Last Updated
April 2, 2025
Record last verified: 2025-03
Datasets originating from our project and used in case of the publication of our results will be deposited on the institutional open access data repository: Yareta and will be made public at the time of the publication. Metadata will be searchable and discoverable. Concerning the mNGS data, in case of scientific publication, raw data will be deposited in the publicly available repository Sequence Read Archive (SRA) from NCBI.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: